home / stock / aadi / aadi news

AADI News and Press, Aadi Bioscience Inc. From 05/11/22

Stock Information
Company Name: Aadi Bioscience Inc.
Stock Symbol: AADI
Market: NASDAQ
Website: aadibio.com
Menu
AADI AADI Quote AADI Short AADI News AADI Articles AADI Message Board
Get AADI Alerts

News, Short Squeeze, Breakout and More Instantly...
AADI - Notable earnings before Thursday's open

AADI,ACHR,ACTG,ADN,AEG,OTCPK:ALIZF,ALT,AMTX,OTCPK:ARNGF,ARQQ,ATY,BAM,BGRY,BKKT,BT,CAMT,CASI,CORR,CPG,CYBR,CYXT,DAVA,DCBO,DRIO,EMAN,EURN,GENI,HIMX,OTCPK:HNHAF,HUT,IS,KNOP,KT,LQDA,MGIC,OTCPK:MKGAF,ML,MOGO,MTNB,NETI,NICE,OTCPK:NSANY,NVMI,ORTX,PCT,OTCPK:PEYUF,OTCQX:QTRHF,RDCM,OTCPK:RWEOY,SCYX,SFL...
AADI - Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

Company enters into collaborations with leading next generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial Collaborations will expedite identification of advanced cancer patients with Tuberous ...

AADI - Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO(TM) from Centers for Medicare and Medicaid Services

LOS ANGELES, May 04, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today reported it has received notification o...

AADI - Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022

LOS ANGELES, April 28, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will report results...
AADI - Aadi Bioscience to Participate at the Jefferies "Biotech on the Bay" Summit

LOS ANGELES, April 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that...

AADI - Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR)

- First rigorous analysis estimates TSC1 and TSC2 definite impact alteration incidence in U.S. as approximately 12,000 advanced cancer patients in 2030 - Findings also identify highest frequency of TSC1 alterations in bladder, kidney, and lung squamous cell cancers, while TSC2 alt...

AADI - Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes

LOS ANGELES, March 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the commencement of dosing in PRECISION 1, a Phase 2 regi...
AADI - Aadi Bioscience GAAP EPS of -$0.77, revenue of $1M

Aadi Bioscience press release (NASDAQ:AADI): Q4 GAAP EPS of -$0.77. License Revenue of $1M. This compares to the $14M license revenue received in 4Q20, related to the non-refundable upfront payment for the rights and license granted to EOC Pharma under the license agreement for the further de...

AADI - Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

-FYARRO™ approved November 22, 2021 and launched February 23, 2022- - FYARRO added to NCCN ® Guidelines as the only preferred therapy to treat malignant PEComa- -PRECISION 1 tumor agnostic study for TSC1 or TSC2 alterations open for enrollment- ...

AADI - Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen's 42nd Annual Health Care Conference

LOS ANGELES, March 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq:AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Offic...
Previous 10 Next 10